Reproductive Health & Fertility

Why GLP-1 Matters Here

Polycystic ovary syndrome is the leading cause of anovulatory infertility in women of reproductive age, affecting an estimated 8 to 13 percent of women globally. The condition is driven by insulin resistance and hyperandrogenism, both of which GLP-1 medications address through their metabolic mechanisms. As GLP-1 therapy reduces insulin resistance, androgen levels normalize and ovarian function resumes in patients who had previously experienced anovulation.

A 2026 randomized trial published in Metabolism and Target Organ Damage demonstrated that semaglutide combined with metformin restored menstrual cyclicity in 86.87 percent of overweight and obese women with PCOS, compared to 60 percent in the control group. Unexpected pregnancies in women previously told they were unlikely to conceive without assisted reproduction have been widely documented, producing what press and clinicians have called the Ozempic babies phenomenon.

Fertility services are seeing a new patient cohort: women who had not expected to conceive without assisted reproduction. Maternity and infant product categories are downstream of that same shift.

What the Data Shows

This vertical has no government fundamentals source. Research citations represent published findings from named organizations using specific methodologies. Search interest reflects consumer information-seeking behavior via Google, which may understate real interest as users migrate to AI search tools.

Analysis

The fertility industry has built significant infrastructure around the assumption that PCOS-related infertility requires medical intervention: hormonal treatments, ovulation induction, IVF cycles. GLP-1 is restoring ovarian function in a substantial proportion of patients before those interventions are needed. That changes the patient journey and the revenue mix for fertility practices, with some procedures declining while monitoring and early-stage consultations increase.

The downstream maternity and infant market effect is less ambiguous. A cohort of women who had not planned to become pregnant is now pregnant. Their purchasing behavior across maternity apparel, infant products, and childcare categories will track with that cohort's growth. The signal is early but directional: GLP-1 adoption is expanding the addressable population for these categories.